Following Trump's election victory, investors responded Wednesday by pouring a lot of money into exchange-traded funds. In this week's ETF Wrap, Christine Idzelis broke down the money flows and the ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

The company's latest presentation supports the idea that its lead program will make billions.

Viking Therapeutics reported updated, early-stage study results on its oral obesity drug candidate. Vertex Pharmaceuticals ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector. YouTuber MrBeast becomes the 8th ...